Citations

Clear

6274 citation(s) found for "To, Andrew".

RNAseq identification of FISH‐cryptic BCL6::TP63 rearrangement in ALK‐negative anaplastic large‐cell lymphoma
Ahmed, Nada, Nowakowski, Grzegorz S. , Dasari, Surendra , Feldman, Andrew L. , Feldman, Andrew L , Ketterling, Rhett P.

Mayo Clinic

Histopathology | May 19, 2022 | Volume: 81 | Issue: 2 | Pages: 275-278

10.1111/his.14674 | PMID 35586895 Get It

Performing parotidectomy postoperative follow-ups via telemedicine: Experience at a tertiary care, multiple-surgeon otolaryngology center
Antezana, Luis A. , Xie, Katherine , Bowen, Andrew J, Yeakel, Sarah, Nassiri, Ashley M. , Moore, Eric J. , Xie, Katherine Z , Antezana, Luis , Yin, Linda X. , Bowen, Andrew J

Mayo Clinic

Journal of Telemedicine and Telecare | May 18, 2022 | Volume: 30 | Issue: 4 | Pages: 739-746

10.1177/1357633x221095319 | PMID 35549759 Get It

Introduction We examined the suitability of using a video visit platform to perform postoperative parotidectomy evaluation at a tertiary care, multiple-surgeon otolaryngology center. Methods A retrospective case review was conducted of patients who underwent parotidectomy and postoperative video visits between November 2019 and December 2020. Success of video visit, plan if applicable, and post-visit outcomes were reviewed. Video visits were designated as successful if the physician could assess for complications in the postoperative course (e.g. first bite pain, Frey syndrome, ear numbness, unplanned visits to the emergency department, unplanned return to the operating room), perform examination of facial nerve function, and formulate care recommendations per clinical judgement without deferment of recommendations for a subsequent in-person visit. Results There were 96 postoperative video visits with 91 unique parotidectomy patients. Demographics: 28/63 male/female; average age, 54y. All video visits were suitable for successful postoperative parotidectomy patient evaluation. Eight visits (8.3%) consisted of patients presenting with common postoperative complications (e.g. eye dryness, first bite pain) and warranted care recommendations. In only two cases did the patient require further in-person procedural (hematoma evacuation, seroma aspiration) follow-ups. For the other 91.7% of visits (n = 88), no additional recommendations were required as patients experienced uncomplicated postoperative courses. Of all the patients, 26.1% (n = 23) were instructed to follow-up for routine surveillance. All other patients, 73.9% (n = 65) were instructed to follow-up as needed. Conclusion Postoperative parotidectomy evaluation is highly amenable to being performed by video. A telemedicine option offers convenience for patients in the majority of cases without compromising clinical assessment and judgment for the physician.
One-year outcomes of catheter ablation for atrial fibrillation in young patients
Patel, Harsh , Patel, Kirtenkumar , Jaswaney, Rahul , Thakkar, Samarthkumar , Kowlgi, Narayan G., Arora, Shilpkumar , Mulpuru, Siva K. , Madhavan, Malini , Killu, Ammar M. , Cha, Yong‐Mei , Deshmukh, Abhishek , Tseng, Andrew S. , Kumar, Ashish , Jani, Chinmay , Kowlgi, Narayan G., Dani, Sourbha S. , DeSimone, Christopher V.

Mayo Clinic

No container title available | May 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1399820/v1 Get It

Abstract Background: Atrial fibrillation (AF) is relatively less frequent in younger patients (age<50). Recently, studies have suggested that early restoration of sinus rhythm may lead to improved outcomes compared with rate control. Methods: We included all hospitalized patients between 18 and 50 years with a diagnosis of AF from the Nationwide Readmission Database 2016-2017 from the Healthcare Cost and Utilization Project. Demographic and comorbidity data were collected and analyzed. Outcomes assessed included one-year AF readmission rates, all-cause readmission, ischemic stroke, and all-cause mortality. Subgroup analyses were performed for all demographic and comorbidity variables.Results: Overall, 52,598 patients (medium age 44, interquartile range 38-48, female 25.7%) were included in the study, including 2,146 (4.0%) who underwent catheter ablation for AF. Patients who underwent catheter ablation had a significantly lower rate of readmission for AF or any cause at one year (adjusted hazard ratios (HR) of 0.52 [95% confidence interval (CI): 0.43-0.63] and HR of 0.81 [95% CI: 0.72 - 0.89], respectively). There was no difference in 1-year readmission for stroke or all-cause mortality between the two groups. Subgroup analyses showed a consistent reduction in the risk of AF readmission among major demographic and comorbidity subgroups.Conclusion: Catheter ablation in young patients with AF was associated with a reduction in 1-year AF related and all-cause readmissions. These data merit further prospective investigation for validation.
Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging
Molinari, Luca , Smith, A.J. Conrad , Landsittel, Douglas , Singbartl, Kai , Yealy, Donald M., Kellum, John A. , Investigators, ProCESS and ProGReSS-AKI, Keener, Christopher, Lucko, Nicole, Pike, Francis, Yende, Sachin , Gimbel, Elizabeth, Landis, Kyle, Stapleton, Diana K., Weissfeld, Lisa A., Willochell, Michael, Wofford, Kourtney A., Watts, Hannah , Venkat, Arvind , Hou, Peter C. , Massaro, Anthony F., Parmar, Siddharth , Brewer, Kori L. , Delbridge, Theodore R. , Mainhart, Allison, Miner, James R. , Allen, Todd L., Grissom, Colin K. , Swadron, Stuart P., Carlson, Richard, LoVecchio, Frank , Parry, Blair A. , Ellender, Timothy J., Sama, Andrew E., Fine, Jonathan , Nafeei, Soheil, Wojnar, Margaret, Pearl, Ronald G. , Wilber, Scott T., Sinert, Richard , Orban, David J., Ufberg, Jacob W. , Albertson, Timothy, Panacek, Edward A., Parekh, Sohan, Gunn, Scott R. , Rittenberger, Jon S., Wadas, Richard J. , Edwards, Andrew R., Holmes, T., Weinert, Craig , Harris, Estelle S. , Self, Wesley H. , Dubinski, Diane, Phillips, Carolyn, Migues, Ronald M., Singbartl, Kai , Kellum, John A , Rio‐Pertuz, Gaspar Del , Palevsky, Paul M. , Chawla, Lakhmir S. , Huang, David T. , Angus, Derek C. , Investigators, ProCESS and ProGReSS-AKI, Barnato, Amber E. , Eaton, Tammy L. , Kulstad, Erik Benjamin , Limkakeng, Alexander T. , Conrad, Steven A. , Bajwa, Ednan K. , Filbin, Michael R. , Terndrup, Thomas E. , Wilson, Jason W. , Kelly, Matthew, Wang, Henry E. , McCurdy, Michael T. , Phillips, Carolyn A

Mayo Clinic

JAMA Network Open | May 18, 2022 | Volume: 5 | Issue: 5 | Pages: e2212709

10.1001/jamanetworkopen.2022.12709 | PMID 35583867 Get It

A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*
Spiegler, Peter, Wesson, Russell , Weldon, Elaina , Dieter, Rebecca A., Quinn, Max M., Mattoo, Aprajita , Soomro, Irfana, Leung, Sherry , Deterville, Cecilia L., Landrum, B. Mark, Ali, Muhammad Imran, Cohen, David J. , Singer, Andrew L., Sen, Ayan , Lonze, Bonnie E. , Alachkar, Nada , Petkova, Eva , Dieter, Rebecca A. , Li, Yi , Cohen, Steven M. , Ali, Muhammad Imran, Chong, Edward, Hochman, Judith S. , Troxel, Andrea B. , Montgomery, Robert A.

Mayo Clinic

Critical Care Medicine | May 18, 2022 | Volume: 50 | Issue: 9 | Pages: 1348-1359

10.1097/ccm.0000000000005591 | PMID 35583232 Get It

OBJECTIVES: We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation. DESIGN: Multicenter, randomized, double-blinded, placebo-controlled, seamless phase II/III trial. SETTING: Five U.S. medical centers. PATIENTS: Adults inpatients with severe COVID-19 disease and hyperinflammation. INTERVENTIONS: Eighty-one patients enrolled in phase II, randomized 1:1:1 to low-dose (12.5 mg) or high-dose (25 mg) clazakizumab or placebo. Ninety-seven patients enrolled in phase III, randomized 1:1 to high-dose clazakizumab or placebo. MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day ventilator-free survival. Secondary outcomes included overall survival, frequency and duration of intubation, and frequency and duration of ICU admission. Per Data Safety and Monitoring Board recommendations, additional secondary outcomes describing clinical status and status changes, as measured by an ordinal scale, were added. Bayesian cumulative proportional odds, logistic, and Poisson regression models were used. The low-dose arm was dropped when the phase II study suggested superiority of the high-dose arm. We report on 152 patients, 74 randomized to placebo and 78 to high-dose clazakizumab. Patients receiving clazakizumab had greater odds of 28-day ventilator-free survival (odds ratio [OR] = 3.84; p [OR > 1] 99.9%), as well as overall survival at 28 and 60 days (OR = 1.75; p [OR > 1] 86.5% and OR = 2.53; p [OR > 1] 97.7%). Clazakizumab was associated with lower odds of intubation (OR = 0.2; p [OR] < 1; 99.9%) and ICU admission (OR = 0.26; p [OR < 1] 99.6%); shorter durations of ventilation and ICU stay (risk ratio [RR] < 0.75; p [RR < 1] > 99% for both); and greater odds of improved clinical status at 14, 28, and 60 days (OR = 2.32, p [OR > 1] 98.1%; OR = 3.36, p [OR > 1] 99.6%; and OR = 3.52, p [OR > 1] 99.8%, respectively). CONCLUSIONS: Clazakizumab significantly improved 28-day ventilator-free survival, 28- and 60-day overall survival, as well as clinical outcomes in hospitalized patients with COVID-19 and hyperinflammation.
Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology
Schofield, Peter R. , Weiner, Michael W. , Xiong, Chengjie , Coble, Dean W. , Saito, Naomi , Aisen, Paul, Berman, Sarah , Cairns, Nigel J., Carrillo, María C. , Chui, Helena C., Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Graff‐Radford, Neill R. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jagust, William J. , Massoumzadeh, Parinaz , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Petersen, Ronald C. , Ringman, John M. , Salloway, Stephen , Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Vöglein, Jonathan , Weninger, Stacie, Bateman, Randall J. , Buckles, Virginia, Morris, John C. , Schofield, Peter R , Gordon, Brian A , Ikeuchi, T , Jack, Clifford R , Jagust, William J , Masters, Colin L , Vöglein, Jonathan , Saykin, Andrew J , Day, Gregory S , Bateman, Randall J , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Xiong, Chengjie , Beckett, Laurel , Allegri, Ricardo , Benzinger, Tammie L.S. , Chui, Helena C. , Cruchaga, Carlos , Ghetti, Bernardino , Ikeuchi, Takeshi , Jucker, Mathias , Martins, Ralph N. , McDade, Eric , Toga, Arthur W.

Mayo Clinic

Brain | May 17, 2022 | Volume: 145 | Issue: 10 | Pages: 3594-3607

10.1093/brain/awac181 | PMID 35580594 Get It

AbstractThe extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of ‘sporadic’ late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease.We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer’s Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset.Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants.These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Cardiovascular Risk Stratification in Diabetic Retinopathy via Atherosclerotic Pathway in COVID-19/Non-COVID-19 Frameworks Using Artificial Intelligence Paradigm: A Narrative Review
Munjral, Smiksha , Maindarkar, Mahesh , Ahluwalia, Puneet , Jujaray, Tanay, Suri, Neha, Paul, Sudip , Saba, Luca , Chalakkal, Renoh Johnson , Gupta, Suneet Kumar , Faa, Gavino , Singh, Inder M. , Chadha, Paramjit S., Turk, Monika, Johri, Amer M. , Khanna, Narendra N. , Višković, Klaudija , Laird, John R. , Pareek, Gyan , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanase D. , Misra, Durga Prasanna , Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Sockalingam, Meyypan, Saxena, Ajit Kumar , Rathore, Vijay , Fatemi, Mostafa , Viswanathan, Vijay , Krishnan, Padukode R., Omerzu, Tomaž , Naidu, Subbaram, Fouda, Mostafa M. , Suri, Jasjit S. , Paul, Sudip , Chalakkal, Renoh Johnson , Faa, Gavino , Viskovic, Klaudija , Sobel, David W , Tsoulfas, George , Protogerou, Athanasios , Agarwal, Vikas , Fatemi, Mostafa , Naidu, Subbaram , Fouda, Mostafa M , Misra, Durga Prasanna , Maindarkar, Mahesh A , Munjral, Smiksha , Puvvula, Anudeep , Jamthikar, Ankush D. , Pathak, Rajesh, Mavrogeni, Sophie , Kitas, George D. , Kolluri, Raghu , Sharma, Aditya , Alizad, Azra , Nicolaides, Andrew , Suri, Jasjit S.

Mayo Clinic

Diagnostics | May 15, 2022 | Volume: 12 | Issue: 5 | Pages: 1234

10.3390/diagnostics12051234 | PMID 35626389 Get It

Diabetes is one of the main causes of the rising cases of blindness in adults. This microvascular complication of diabetes is termed diabetic retinopathy (DR) and is associated with an expanding risk of cardiovascular events in diabetes patients. DR, in its various forms, is seen to be a powerful indicator of atherosclerosis. Further, the macrovascular complication of diabetes leads to coronary artery disease (CAD). Thus, the timely identification of cardiovascular disease (CVD) complications in DR patients is of utmost importance. Since CAD risk assessment is expensive for low-income countries, it is important to look for surrogate biomarkers for risk stratification of CVD in DR patients. Due to the common genetic makeup between the coronary and carotid arteries, low-cost, high-resolution imaging such as carotid B-mode ultrasound (US) can be used for arterial tissue characterization and risk stratification in DR patients. The advent of artificial intelligence (AI) techniques has facilitated the handling of large cohorts in a big data framework to identify atherosclerotic plaque features in arterial ultrasound. This enables timely CVD risk assessment and risk stratification of patients with DR. Thus, this review focuses on understanding the pathophysiology of DR, retinal and CAD imaging, the role of surrogate markers for CVD, and finally, the CVD risk stratification of DR patients. The review shows a step-by-step cyclic activity of how diabetes and atherosclerotic disease cause DR, leading to the worsening of CVD. We propose a solution to how AI can help in the identification of CVD risk. Lastly, we analyze the role of DR/CVD in the COVID-19 framework.
Efficacy and safety of endoscopic ultrasound-guided gastrojejunostomy in patients with malignant gastric outlet obstruction and ascites
Mahmoud, Tala , Law, Ryan , Jaruvongvanich, Veeravich , Ghazi, Rabih , Abusaleh, Rami , Levy, Michael J. , Truty, Mark J. , Law, Ryan J, Storm, Andrew C. , Vargas, Eric J. , Bazerbachi, Fateh , Levy, Michael J. , Chandrasekhara, Vinay , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | May 13, 2022 | Volume: 10 | Issue: 05 | Pages: E670-E678

10.1055/a-1797-9318 | PMID 35571468 Get It

Abstract Background and study aims Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) is an endoscopic procedure for treating gastric outlet obstruction (GOO). Limited data exist regarding the safety and efficacy of EUS-GJ in patients with malignant GOO with ascites. Thus, we aimed to study the outcomes and safety of EUS-GJ in GOO patients with vs. without ascites. Patients and methods This is a retrospective cohort study of patients with malignant GOO who underwent successful EUS-GJ at a tertiary care academic center. Primary outcomes included the efficacy and safety of EUS-GJ. Secondary outcomes included 30-day readmission, reintervention, and survival utilizing Kaplan-Meier analysis. Results A total of 55 patients (mean age of 67.0 ± 11.3 years, 40.0 % female) who underwent EUS-GJ, of whom 24 had ascites (small in 22, large in 2) were included. Clinical success was achieved in 91.7 % and 93.5 % (P = 1.00) of patients with and without ascites, respectively. A higher rate of adverse events (AEs) was noted in patients with ascites but this was not statistically significant (37.5 % vs. 19.4 %, P = 0.13). Four patients in the ascites group (16.6 %) developed clinical evidence of peritonitis or sepsis post-EUS-GJ. Eight patients with ascites developed worsening ascites within a month of EUS-GJ. In contrast, only one patient without ascites developed evidence of new ascites. The median survival of patients was not significantly different between the two groups (patients with ascites: 129 days vs. patients without ascites: 180 days, (P = 0.12). Conclusions The efficacy EUS-GJ in the presence of ascites is promising; however, the safety profile remains concerning given the high rate of AEs, specifically peritonitis and sepsis.
Predictive Modeling of New-Onset Postoperative Diplopia Following Orbital Decompression for Thyroid Eye Disease
Nair, Archana , Ediriwickrema, Lilangi S. , Dolman, Peter J. , Law, Geoffrey , Harrison, Andrew R. , Mokhtarzadeh, Ali , Stewart, Krista J., Men, Clara J. , Lucarelli, Mark J., Landingham, Suzanne van, Wingelaar, Maxwell , Verma, Rohan , Chen, Allison , Selva, Dinesh , Garrity, James, Eckel, Laurence J. , Kazim, Michael, Godfrey, Kyle J. , Korn, Bobby S. , Kikkawa, Don O. , Eckel, Laurence, Stewart, Krista, Landingham, Suzanne W. van , Baxter, Sally L.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | May 13, 2022 | Volume: 38 | Issue: 6 | Pages: 551-557

10.1097/iop.0000000000002196 | PMID 35551414 Get It

Purpose: To identify risk factors for the development of new-onset, postoperative diplopia following orbital decompression surgery based on patient demographics, clinical exam characteristics, radiographic parameters, and surgical techniques. Methods: We conducted a multi-center retrospective chart review of patients who underwent orbital decompression for thyroid eye disease (TED). Patient demographics, including age, gender, smoking history, preoperative exophthalmometry, clinical activity score (CAS), use of peribulbar and/or systemic steroids, and type of orbital decompression were reviewed. Postoperative diplopia was determined at a minimum of 3 months postoperatively and before any further surgeries. Cross-sectional area ratios of each extraocular muscle to orbit and total fat to orbit were calculated from coronal imaging in a standard fashion. All measurements were carried out using PACS imaging software. Multivariable logistic regression modeling was performed using Stata 14.2 (StataCorp, College Station, TX). Results: A total of 331 patients without preoperative diplopia were identified. At 3 months postoperatively, 249 patients had no diplopia whereas 82 patients developed diplopia. The average postoperative follow-up was 22 months (range 3–156) months. Significant preoperative clinical risk factors for postoperative diplopia included older age at surgery, proptosis, use of peribulbar or systemic steroids, elevated clinical activity score, and presence of preoperative compressive optic neuropathy. Imaging findings of enlarged cross-sectional areas of each rectus muscle to the overall orbital area also conferred a significant risk of postoperative diplopia. Regarding surgical factors, postoperative diplopia was more common among those undergoing medial wall decompression, bilateral orbital surgery, and balanced decompression, whereas endoscopic medial wall decompression was found to be relatively protective. Conclusions: This study identifies risk factors associated with the development of diplopia following orbital decompression using multivariable data. This study demonstrates that several characteristics including age, clinical activity score, the cross-sectional muscle to orbit ratios, in addition to the type of orbital decompression surgery, are predictive factors for the development of new-onset postoperative diplopia.
Outpatient versus inpatient lumbar decompression surgery: a matched noninferiority study investigating clinical and patient-reported outcomes
Mooney, James , Michalopoulos, Giorgos D. , Zeitouni, Daniel , Sammak, Sally El , Alvi, Mohammed Ali , Wang, Michael Y. , Coric, Domagoj , Chan, Andrew K. , Mummaneni, Praveen V. , Bisson, Erica F. , Sherrod, Brandon A. , Haid, Regis W., Knightly, John J. , Devin, Clinton J. , Pennicooke, Brenton , Asher, Anthony L. , Bydon, Mohamad , Alvi, Mohammed Ali , Michalopoulos, Giorgos

Mayo Clinic

Journal of Neurosurgery: Spine | May 13, 2022 | Volume: 37 | Issue: 4 | Pages: 485-497

10.3171/2022.3.spine211558 | PMID 35523251 Get It

OBJECTIVE Spine surgery represents an ideal target for healthcare cost reduction efforts, with outpatient surgery resulting in significant cost savings. With an increased focus on value-based healthcare delivery, lumbar decompression surgery has been increasingly performed in the outpatient setting when appropriate. The aim of this study was to compare clinical and patient-reported outcomes following outpatient and inpatient lumbar decompression surgery. METHODS The Quality Outcomes Database (QOD) was queried for patients undergoing elective one- or two-level lumbar decompression (laminectomy or laminotomy with or without discectomy) for degenerative spine disease. Patients were grouped as outpatient if they had a length of stay (LOS) < 24 hours and as inpatient if they stayed in the hospital ≥ 24 hours. Patients with ≥ 72-hour stay were excluded from the comparative analysis to increase baseline comparability between the two groups. To create two highly homogeneous groups, optimal matching was performed at a 1:1 ratio between the two groups on 38 baseline variables, including demographics, comorbidities, symptoms, patient-reported scores, indications, and operative details. Outcomes of interest were readmissions and reoperations at 30 days and 3 months after surgery, overall satisfaction, and decrease in Oswestry Disability Index (ODI), back pain, and leg pain at 3 months after surgery. Satisfaction was defined as a score of 1 or 2 in the North American Spine Society patient satisfaction index. Noninferiority of outpatient compared with inpatient surgery was defined as risk difference of < 1.5% at a one-sided 97.5% confidence interval. RESULTS A total of 18,689 eligible one- and two-level decompression surgeries were identified. The matched study cohorts consisted of 5016 patients in each group. Nonroutine discharge was slightly less common in the outpatient group (0.6% vs 0.3%, p = 0.01). The 30-day readmission rates were 4.4% and 4.3% for the outpatient and inpatient groups, respectively, while the 30-day reoperation rates were 1.4% and 1.5%. The 3-month readmission rates were 6.3% for both groups, and the 3-month reoperation rates were 3.1% for the outpatient cases and 2.9% for the inpatient cases. Overall satisfaction at 3 months was 88.8% for the outpatient group and 88.4% for the inpatient group. Noninferiority of outpatient surgery was documented for readmissions, reoperations, and patient-reported satisfaction from surgery. CONCLUSIONS Outpatient lumbar decompression surgery demonstrated slightly lower nonroutine discharge rates in comparison with inpatient surgery. Noninferiority in clinical outcomes at 30 days and 3 months after surgery was documented for outpatient compared with inpatient decompression surgery. Additionally, outpatient decompression surgery performed noninferiorly to inpatient surgery in achieving patient satisfaction from surgery.